RD-LPS treatment prevented sepsis and activated the bone marrow function in these patients.
TOLERIN treatment prevented sepsis and activated bone marrow function in these patients.
Bone marrow function was monitored during treatment in terms of Hb, WBC and PLT counts in blood every other week.
Patients were monitored according to bone marrow function (Hb, WBC, and PLT counts) by blood sampling every 2 weeks during the treatment period.
Umbilical cord blood (UCB) is an accepted treatment for the reconstitution of bone marrow function following myeloablative treatment predominantly in children and juveniles.
In contrast, bone marrow dosimetry is only performed occasionally, and instead haematological toxicity monitored in terms of haemoglobin (Hb), white blood cell (WBC) and platelet (PLT) counts serves as a surrogate of bone marrow function.
The need for individual BM dosimetry grows as the total amount of 177Lu-DOTATATE given tends to increase and future treatment options make it necessary to preserve bone marrow function.
Adverse effects included grade 2 suppression of bone marrow function, hair loss, and GI symptoms such as diarrhea, and vomiting that were tolerable and managed by reducing administration dose to 80% of the initial dosage without discontinuation of the chemotherapy.
To date, there have been no studies of spleen or bone marrow function in S. araneus.
Adequate hepatic, renal and bone marrow function were required.
– Inadequate bone marrow function to undergo planned therapy.
